Click on a filter below to refine your search. Remove a filter to broaden your search.
CMS says a final decision on coverage is not likely until next spring.
The announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year.
Serum lutein+zeaxanthin and β-cryptoxanthin levels were inversely associated with incident all-cause dementia.
The decision is meant to protect patients while gathering more clinical data on whether the medication actually helps slow declines in thinking.
Medicare spending was higher for adults with a formal clinical diagnosis of dementia versus a positive screening for cognitive impairment.
Immediate and lasting reductions were seen in the share of patients receiving hospice care with the Alzheimer’s disease and related dementia code.
The percentage of older U.S. decedents with a diagnosis of Alzheimer’s disease and related dementias increased significantly from 2004 to 2017.
New premium will be $170.10 a month, and the $21.60 boost is the biggest increase ever in dollar amount, but not in percentage terms
But the biggest policy change — letting Medicare negotiate prices for prescription drugs — will not start to lower costs until 2025.
Major changes to prescribing instructions are rare, especially so soon after approval; it change could curb the drug’s use.